Grosse Pointe Farms, United States
SciTech Development is a Specialty Pharmaceutical Company focused on advancing breakthrough cancer treatments. The company's proprietary drug delivery platform, SDP, and lead cancer drug candidate, ST-001 nanoFenretinide, showcase considerable potential in developing cost-effective therapeutics with transformative clinical outcomes.
Their patent-protected ST-001-nanoFenretinide, which combines SDP and the drug fenretinide, is designed to effectively target incurable cancers with low-risk, proven safety and efficacy from previous clinical trials, making it clinical trial ready.
SciTech's immediate goal is to commercialize ST-001 and establish strategic partnerships with pharmaceutical industry leaders to expand their oncology drug portfolio, target new diseases, or develop combination drug therapies.
The FDA's approval of IND for T-Cell Lymphomas, Phase 1a/b clinical trial plan, IRB approval by Rush University Medical Center, and Orphan Drug Designation for several T-cell lymphomas demonstrate the company's significant achievements.
With a recent $3.20M Venture Round investment on 04 June 2024, led by Storm Lake Capital and Pointe Angels, SciTech Development LLC is poised to revolutionize cancer treatment with its innovative drug delivery platform and lead cancer drug candidate, marking a promising venture for potential investors.
